tiprankstipranks
Trending News
More News >

Clene initiated with a Buy at JonesResearch

JonesResearch analyst Justin Walsh initiated coverage of Clene (CLNN) with a Buy rating and $30 price target Clene is a clinical-stage pharmaceutical company developing nanothechnology therapeutics for the treatment of central nervous system disorders, the analyst tells investors in a research note. The firm says the company’s clinical setbacks in amyotrophic lateral sclerosis “are not the end of the story.” The market has written off potential accelerated approval prematurely, contends JonesResearch.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue